Attack ChainAIDerived
Hypothetical attack flow derived from CVE metadata – not a confirmed exploit chain
-
AccessObtain low-privilege Empirica Signal account
-
DeliveryReach Common Core HTTP interface
-
ExploitSend crafted request bypassing access control
-
ExecutionRead, modify or delete critical safety data
-
ImpactScope change impacts integrated products
Vulnerability Assessment
| Weakness |
CWE
OWASP Top 10:2025
A01:2025 - Broken Access Control
ASVS 5.0
V8 - Authorization Access control enforcement
MITRE ATT&CK
1 technique across 1 tactic: Defense Evasion The technique list with ATT&CK links and the kill-chain view is part of the Basic plan and up. |
| Exploitation Conditions | Requires a valid low-privilege authenticated account on Oracle Life Sciences Empirica Signal (CVSS PR:L) with network reachability to the application's HTTP interface (AV:N); no user interaction and low attack complexity are needed (UI:N/AC:L). Affected deployments are limited to supported versions 9.2.1 through 9.2.3 running the Common Core component. The primary limiting factor is the authentication requirement - an attacker must already possess or obtain low-privilege credentials - so unauthenticated internet-facing exploitation is not supported by the CVSS vector despite the 'Authentication Bypass' tag; the scope change (S:C) means successful exploitation can reach data or products under a separate security authority. |
| Impact | Signals here are mixed and lean toward moderate real-world urgency rather than emergency. CVSS 3.1 is 8.5 (High), driven by network vector (AV:N), low complexity (AC:L), no user interaction (UI:N), scope change (S:C), and high integrity impact (I:H) - but it explicitly requires privileges (PR:L), so this is not an unauthenticated flaw. Counterbalancing the high CVSS, EPSS is only 0.03% (8th percentile) and CISA SSVC records Exploitation: none, Automatable: no, Technical Impact: partial - all indicating low likelihood of imminent, widespread exploitation. There is no KEV listing and no public exploit identified at time of analysis. Note a tension worth verifying: the 'Authentication Bypass' tag implies pre-auth access, yet the CVSS vector requires PR:L (an authenticated low-privilege account) - the description's 'low privileged attacker' should be treated as authoritative, so an attacker needs at least a valid low-privilege account. Net: a genuine High-severity integrity/access-control issue, but current exploitation pressure is low. |
| Exploit ScenarioDerived | A user holding a low-privilege Empirica Signal account authenticates over HTTP and sends crafted requests that bypass access-control checks in the Common Core component, allowing them to modify or delete critical safety/signal data and read data they should not see. Because of the scope change, the impact can extend to integrated products beyond Empirica Signal itself. No public exploit code is known, so an attacker would need to develop the technique independently. |
Get an e-mail when this CVE is exploited, patched or re-scored. Free account.
Alert meAnalysisAIv1 – Jul 24, 2026
Unauthorized data manipulation in Oracle Life Sciences Empirica Signal 9.2.1 through 9.2.3 (Common Core component) allows a low-privileged, network-authenticated attacker to create, delete, or modify critical data and read a subset of accessible data over HTTP. The scope-changed flaw (rooted in improper access control, CWE-284) can significantly impact additional products beyond Empirica Signal itself, and Oracle rates it CVSS 3.1 8.5. There is no public exploit identified at time of analysis, and EPSS is very low at 0.03% (8th percentile).
RemediationAI
Apply the fixes delivered in the Oracle Critical Patch Update of April 2026 (https://www.oracle.com/security-alerts/cpuapr2026.html); this is Patch available per vendor advisory, as Oracle CPU releases bundle the corrective patches for Empirica Signal 9.2.1-9.2.3 (no standalone fixed version string is provided in the input, so confirm the exact patch level from the CPU matrix). Because exploitation requires a low-privilege authenticated account, compensating controls until patching include tightening account provisioning and role assignments, revoking or auditing unnecessary low-privilege user accounts, and enforcing least privilege so fewer users can reach the Common Core functionality; restrict network access to the Empirica Signal HTTP interface to trusted clinical/pharmacovigilance networks or via VPN to reduce the reachable attacker population, accepting that this may inconvenience remote or partner users. Monitor application audit logs for anomalous create/delete/modify activity on critical safety data as a detection control. These are mitigations, not substitutes for the CPU patch.
Affects your stack
Find out whether the stacks and servers you run are on an affected version.
Checking this CVE against your own stacks and servers is part of the Basic plan and up.
Technical ContextAI · show details
Empirica Signal is Oracle's pharmacovigilance and drug-safety signal-detection platform used in life-sciences and clinical safety workflows; the affected 'Common Core' component underpins shared services across the application. The root cause is classified as CWE-284 (Improper Access Control), and the vendor/tag data characterizes it as an authentication/authorization bypass - meaning an already-authenticated low-privilege user can reach functionality or data that access-control checks should restrict. The CPE cpe:2.3:a:oracle_corporation:oracle_life_sciences_empirica_signal identifies the affected application, and the CVSS scope-change flag (S:C) indicates the vulnerable component can grant impact to resources managed by a different security authority (e.g., integrated back-end products or shared data stores).
Know when Oracle Life Sciences Empirica Signal gets its next vulnerability
- Watch products and get an email when something new is published
- Check this CVE against your own stack and servers
- Exploit and PoC references, threat intelligence from 22 sources
No credit card · 7-day full trial
Severity by source
AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:H/A:N
Network HTTP access with low complexity and a required low-privilege account gives AV:N/AC:L/PR:L; access-control bypass yields high integrity, limited confidentiality, no availability, with scope change per vendor.
Primary rating from Vendor (oracle).
CVSS VectorVendor: oracle
DescriptionCVE.org
Vulnerability in the Oracle Life Sciences Empirica Signal product of Oracle Life Science Applications (component: Common Core). Supported versions that are affected are 9.2.1-9.2.3. Easily exploitable vulnerability allows low privileged attacker with network access via HTTP to compromise Oracle Life Sciences Empirica Signal. While the vulnerability is in Oracle Life Sciences Empirica Signal, attacks may significantly impact additional products (scope change). Successful attacks of this vulnerability can result in unauthorized creation, deletion or modification access to critical data or all Oracle Life Sciences Empirica Signal accessible data as well as unauthorized read access to a subset of Oracle Life Sciences Empirica Signal accessible data. CVSS 3.1 Base Score 8.5 (Confidentiality and Integrity impacts). CVSS Vector: (CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:H/A:N).
Threat Intelligence Overview
How this decision was reached
The engine reads each signal below and applies a fixed list of rules from top to bottom. The first rule that matches sets the recommended action – like a statement, every line is shown.
What every action level means
SSVC AssessmentENISA
Priority Score
Attack Technique
Authentication bypass attacks exploit flaws in the verification mechanisms that control access to systems and applications.
EUVD-2026-24293
GHSA-fjgq-vg76-2mmp
NVD
CVE.org
EPSS
Vulnrichment
Exploit-DB